Is xyosted a controlled substance?

What are the regulatory classifications of xyosted?

Xyosted, also known as niferelimab, is an anabolic steroid drug that is used in the treatment of certain conditions.

Xyosted is classified as a schedule III controlled substance in the United States, according to the Controlled Substances Act (CSA) [1]. This scheduling indicates that while it has a potential for abuse and dependency, it also has a currently accepted medical use in the treatment of certain medical conditions when used under a healthcare provider's supervision.

Why is xyosted regulated as a controlled substance?

As a synthetic testosterone-derived anabolic steroid, xyosted can be abused for its performance-enhancing effects or other non-medical uses [2]. The CSA regulates the use and distribution of controlled substances to prevent such abuse, while ensuring that they remain accessible to patients under proper medical supervision for legitimate, medical purposes.

How does the classification of xyosted as a schedule III controlled substance impact its prescription and use?

As a controlled substance, Xyosted prescriptions are subject to certain regulations and security measures to mitigate potential diversion or abuse [3]. For example, the prescribing provider must maintain accurate records of controlled substances dispensed, and patients receiving xyosted prescriptions may be subject to more rigorous monitoring to ensure their prescriptions are being used for legitimate medical purposes.

What sources of information are available on the regulation of xyosted and other controlled substances?

More information on the regulatory classifications of controlled substances, including xyosted, can be found on websites such as the U.S. Drug Enforcement Administration (DEA) or the National Library of Medicine (NLM).

References:

[1] Controlled Substances Act, 21 U.S.C. § 812
[2] DrugPatentWatch.com - xyosted patent information
[3] Prescription opioid abuse: a report by the President's Commission on Combating Drug Addiction and the Opioid Crisis

Sources:

* U.S. Drug Enforcement Administration (DEA)
* National Library of Medicine (NLM)
* DrugPatentWatch.com